Selective modification of fluciclovine (18F) transport in prostate carcinoma xenografts
- 121 Downloads
We investigated if previously demonstrated inhibition of fluciclovine (18F) in vitro could be replicated in a PC3-Luc xenograft mouse model. Following intratumoral injection of 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid (BCH), alpha-(methylamino)isobutyric acid (MeAIB) or saline, fluciclovine PET tumor-to-background activity was 43.6 (± 5.4)% and 25.3 (± 5.2)% lower in BCH (n = 6) and MeAIB (n = 5) injected PC3 Luc xenografts, respectively, compared to saline-injected controls (n = 2). Partial inhibition of fluciclovine uptake by BCH and MeAIB can be demonstrated in vivo similar to previous in vitro modeling.
KeywordsFluciclovine Prostate cancer PC3 Amino acid transport Axumin
Research reported in this publication was supported in part by the Cancer Animal Models Shared Resource, a core supported by the Winship Cancer Institute of Emory University and Cancer Center Support Grant P30 CA138292.
This study was otherwise internally funded.
Compliance with ethical standards
Conflict of interest
Emory University licensed and approved the 18F-fluciclovine patent technology in accordance with the Emory Conflict of Interest Committee policies. M. M. Goodman and Emory University are eligible to receive royalties derived from the sale of 18F-fluciclovine. H. Okudaira and S. Oka are employees of Nihon Medi-Physics Co., Ltd. (NMP) and collaborate with M. M. Goodman and D. M. Schuster on preclinical and clinical studies involving 18F-fluciclovine. F. I. Tade, O. Akin-Akintayo, and D. M. Schuster receive funding/resources from Blue Earth Diagnostics Ltd. and Nihon Medi-Physics Co., Ltd. through the Emory University Office of Sponsored Projects for research outside that reported in this manuscript. All other co-authors declared no conflicts of interest.
Research involving human participants and/or animals
This study was performed with the approval of the Institutional Animal Care and Use Committee. All procedures performed in this study using animals were in accordance with institutional and/or national guidelines and ethical standards for the care and use of animals. No human studies were conducted.
No human studies were conducted.
- Oka S, Okudaira H, Ono M et al (2014) Differences in transport mechanisms of trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid in inflammation, prostate cancer, and glioma cells: comparison with l-[methyl-11C]methionine and 2-deoxy-2-[18F]fluoro-d-glucose. Mol Imaging Biol 16(3):322–329. https://doi.org/10.1007/s11307-013-0693-0 CrossRefPubMedGoogle Scholar
- Okudaira H, Oka S, Ono M et al (2014) Accumulation of trans-1-amino-3-[(18)F]fluorocyclobutanecarboxylic acid in prostate cancer due to androgen-induced expression of amino acid transporters. Mol Imaging Biol 16(6):756–764. https://doi.org/10.1007/s11307-014-0756-x CrossRefPubMedPubMedCentralGoogle Scholar
- Ono M, Oka S, Okudaira H et al (2013) Comparative evaluation of transport mechanisms of trans-1-amino-3-[(1)(8)F]fluorocyclobutanecarboxylic acid and l-[methyl-(1)(1)C]methionine in human glioma cell lines. Brain Res 1535:24–37. https://doi.org/10.1016/j.brainres.2013.08.037 CrossRefPubMedGoogle Scholar
- Schuster DM, Savir-Baruch B, Nieh PT et al (2011) Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT. Radiology 259(3):852–861. https://doi.org/10.1148/radiol.11102023 CrossRefPubMedPubMedCentralGoogle Scholar
- Schuster DM, Nanni C, Fanti S et al (2014a) Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid: physiologic uptake patterns, incidental findings, and variants that may simulate disease. J Nucl Med Off Publ Soc Nucl Med 55(12):1986–1992. https://doi.org/10.2967/jnumed.114.143628 CrossRefGoogle Scholar
- Schuster DM, Nieh PT, Jani AB et al (2014b) Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial. J Urol 191(5):1446–1453. https://doi.org/10.1016/j.juro.2013.10.065 CrossRefPubMedGoogle Scholar